Table 3B.
Mφ | Autoimmune diseases | Cardiovascular diseases | Digestive inflammatory | Infection diseases | Metabolic diseases | Respiratory diseases | Digestive tumors | Other tumors | Up-regulated disease | Down-regulated disease | |||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Subsets | TFs | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | Number | % | Number | % |
M1 | HIF1A | ↓ | ↑ | ↑ | ↑ | ↓ | ↓ | ↓ | ↓ | ↑ | ↑ | ↑ | ↓ | 6 | 17.6 | 6 | 17.6 | ||||||||||||||||||||||
RELA | ↓ | ↓ | ↑ | 1 | 2.9 | 2 | 5.9 | ||||||||||||||||||||||||||||||||
IRF3 | ↓ | ↓ | ↑ | ↑ | 2 | 5.9 | 2 | 5.9 | |||||||||||||||||||||||||||||||
STAT1 | ↑ | ↑ | ↑ | ↑ | ↓ | ↑ | ↑ | ↑ | ↓ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | 17 | 50.0 | 2 | 5.9 | ||||||||||||||||
STAT2 | ↓ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↓ | ↑ | ↑ | 9 | 26.5 | 2 | 5.9 | ||||||||||||||||||||||||
M2a | PPARD | ↑ | ↑ | ↑ | ↑ | ↓ | ↓ | ↑ | ↑ | ↓ | ↑ | ↑ | 8 | 23.5 | 3 | 8.8 | |||||||||||||||||||||||
PPARG | ↓ | ↑ | ↑ | ↓ | ↓ | ↓ | ↓ | ↓ | ↑ | ↑ | ↑ | ↓ | ↑ | ↑ | ↓ | ↓ | 7 | 20.6 | 9 | 26.5 | |||||||||||||||||||
KLF4 | ↓ | ↓ | ↓ | ↓ | ↓ | ↓ | ↓ | ↓ | ↑ | ↓ | ↓ | ↓ | ↓ | ↓ | 1 | 2.9 | 13 | 38.2 | |||||||||||||||||||||
AKT1 | ↓ | ↑ | 1 | 2.9 | 1 | 2.9 | |||||||||||||||||||||||||||||||||
M2b | MAPK1 | ↑ | ↑ | ↑ | ↓ | ↓ | ↑ | ↓ | ↓ | ↑ | 5 | 14.7 | 4 | 11.8 | |||||||||||||||||||||||||
STAT3 | ↑ | ↑ | ↓ | ↑ | ↑ | ↓ | ↑ | ↑ | ↑ | ↓ | ↑ | ↓ | 8 | 23.5 | 4 | 11.8 | |||||||||||||||||||||||
M2c | NFKB1 | ↑ | ↓ | ↓ | 1 | 2.9 | 2 | 5.9 | |||||||||||||||||||||||||||||||
NFKB2 | ↓ | ↑ | ↑ | ↓ | ↑ | ↑ | ↑ | ↑ | 6 | 17.6 | 2 | 5.9 | |||||||||||||||||||||||||||
NR3C1 | ↓ | ↓ | ↑ | ↓ | ↑ | ↓ | ↓ | ↓ | ↓ | ↓ | ↓ | ↓ | ↓ | ↑ | 3 | 8.8 | 11 | 32.4 | |||||||||||||||||||||
NFE2 | ↑ | ↓ | ↑ | ↑ | ↓ | ↑ | ↑ | ↓ | ↑ | ↓ | 6 | 17.6 | 4 | 11.8 | |||||||||||||||||||||||||
Mhb | ATF1 | ↑ | ↓ | ↓ | ↓ | ↓ | ↑ | ↓ | ↓ | 2 | 5.9 | 6 | 17.6 | ||||||||||||||||||||||||||
Mox | NR1H3 | ↑ | ↓ | ↑ | ↓ | ↑ | ↑ | 4 | 11.8 | 2 | 5.9 | ||||||||||||||||||||||||||||
Mhem | NR1H2 | ↑ | ↓ | ↑ | ↓ | ↓ | ↑ | 3 | 8.8 | 3 | 8.8 | ||||||||||||||||||||||||||||
NR1H3 | ↑ | ↓ | ↑ | ↓ | ↑ | ↑ | 4 | 11.8 | 2 | 5.9 | |||||||||||||||||||||||||||||
uncertain | CREB1 | ↑ | ↓ | ↓ | ↓ | ↓ | ↑ | ↑ | ↓ | ↑ | 4 | 11.8 | 5 | 14.7 | |||||||||||||||||||||||||
HMGA1 | ↑ | ↑ | ↑ | ↓ | ↓ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | 11 | 32.4 | 2 | 5.9 | ||||||||||||||||||||||
SMAD4 | ↓ | ↑ | ↓ | ↓ | ↑ | ↓ | ↓ | ↑ | ↓ | ↓ | ↓ | ↓ | ↓ | ↓ | ↓ | ↓ | 3 | 8.8 | 13 | 38.2 | |||||||||||||||||||
ZNF148 | ↓ | ↓ | ↓ | ↓ | ↑ | ↑ | ↓ | ↑ | 3 | 8.8 | 5 | 14.7 | |||||||||||||||||||||||||||
HBP1 | ↓ | ↓ | ↓ | ↓ | ↑ | ↓ | ↓ | ↓ | 1 | 2.9 | 7 | 20.6 | |||||||||||||||||||||||||||
CKLF | ↑ | ↑ | ↓ | ↑ | ↓ | ↓ | ↓ | ↑ | ↑ | ↑ | ↑ | ↑ | 8 | 23.5 | 4 | 11.8 | |||||||||||||||||||||||
ZNF281 | ↑ | ↑ | ↑ | ↓ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | 9 | 26.5 | 1 | 2.9 | |||||||||||||||||||||||||
FOXO3 | ↓ | ↓ | ↓ | ↓ | ↓ | ↓ | 0 | 0.0 | 6 | 17.6 | |||||||||||||||||||||||||||||
HEY1 | ↑ | ↑ | ↓ | ↑ | ↓ | ↓ | ↑ | ↓ | ↑ | ↑ | ↓ | ↑ | ↓ | ↓ | ↓ | ↑ | 8 | 23.5 | 8 | 23.5 | |||||||||||||||||||
ETS2 | ↓ | ↓ | ↓ | ↓ | ↓ | ↑ | ↓ | ↓ | ↑ | ↓ | ↑ | ↑ | ↑ | ↓ | ↓ | ↓ | 6 | 17.6 | 11 | 32.4 | |||||||||||||||||||
HIF1A | ↑ | ↓ | ↑ | ↑ | ↑ | ↑ | ↓ | ↓ | ↑ | ↑ | ↑ | ↓ | 8 | 23.5 | 4 | 11.8 | |||||||||||||||||||||||
STAT4 | ↓ | ↑ | ↓ | ↑ | 2 | 5.9 | 2 | 5.9 | |||||||||||||||||||||||||||||||
MELTF | ↓ | ↑ | ↓ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | 7 | 20.6 | 2 | 5.9 | ||||||||||||||||||||||||||
BATF3 | ↑ | ↑ | ↑ | 3 | 8.8 | 0 | 0.0 | ||||||||||||||||||||||||||||||||
NFE2 | ↑ | ↑ | ↓ | ↑ | ↑ | ↓ | ↑ | ↓ | ↑ | ↓ | 6 | 17.6 | 4 | 11.8 | |||||||||||||||||||||||||
NFKB1 | ↑ | ↓ | ↓ | 1 | 2.9 | 2 | 5.9 | ||||||||||||||||||||||||||||||||
RIT1 | ↑ | ↑ | ↑ | ↑ | ↓ | ↓ | ↓ | ↑ | ↑ | ↓ | ↑ | ↓ | ↑ | 8 | 23.5 | 5 | 14.7 | ||||||||||||||||||||||
HIVEP1 | ↑ | ↓ | ↓ | ↑ | 2 | 5.9 | 2 | 5.9 | |||||||||||||||||||||||||||||||
JUNB | ↓ | ↑ | ↑ | ↓ | ↓ | ↓ | ↑ | ↓ | ↑ | ↓ | ↓ | 4 | 11.8 | 7 | 20.6 | ||||||||||||||||||||||||
NFX1 | ↓ | ↑ | ↓ | ↑ | ↓ | ↑ | ↑ | 4 | 11.8 | 3 | 8.8 | ||||||||||||||||||||||||||||
FOXN3 | ↓ | ↓ | ↓ | ↓ | ↓ | ↓ | ↓ | ↑ | ↓ | ↓ | ↓ | ↓ | ↓ | 1 | 2.9 | 12 | 35.3 | ||||||||||||||||||||||
STAT3 | ↑ | ↓ | ↑ | ↑ | ↓ | ↑ | ↓ | ↓ | ↑ | ↑ | ↓ | ↑ | ↓ | 7 | 20.6 | 6 | 17.6 | ||||||||||||||||||||||
PWWP3A | 0 | 0.0 | 0 | 0.0 | |||||||||||||||||||||||||||||||||||
MXD4 | ↓ | ↓ | ↑ | ↓ | ↓ | ↓ | 1 | 2.9 | 5 | 14.7 | |||||||||||||||||||||||||||||
E2F3 | ↑ | ↓ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | 13 | 38.2 | 1 | 2.9 | |||||||||||||||||||||
CEBPD | ↓ | ↑ | ↑ | ↓ | ↓ | ↓ | ↓ | ↓ | 2 | 5.9 | 6 | 17.6 | |||||||||||||||||||||||||||
NME1 | ↑ | ↑ | ↓ | ↓ | ↑ | ↑ | ↑ | ↓ | ↓ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | 12 | 35.3 | 4 | 11.8 | |||||||||||||||||||
Up- regulated gene |
Number | 5 | 0 | 4 | 1 | 8 | 18 | 0 | 4 | 7 | 1 | 9 | 18 | 0 | 2 | 2 | 7 | 2 | 1 | 2 | 2 | 0 | 7 | 0 | 4 | 8 | 9 | 5 | 17 | 13 | 6 | 5 | 13 | 19 | 12 | ||||
% | 12.2 | 0.0 | 9.8 | 2.4 | 19.5 | 43.9 | 0.0 | 9.8 | 17.1 | 2.4 | 22.0 | 43.9 | 0.0 | 4.9 | 4.9 | 17.1 | 4.9 | 2.4 | 4.9 | 4.9 | 0.0 | 17.1 | 0.0 | 9.8 | 19.5 | 22.0 | 12.2 | 41.5 | 31.7 | 14.6 | 12.2 | 31.7 | 46.3 | 26.8 | |||||
Down-regulated gene | Number | 9 | 1 | 1 | 1 | 6 | 4 | 8 | 18 | 2 | 0 | 4 | 8 | 28 | 0 | 0 | 6 | 12 | 0 | 6 | 3 | 0 | 2 | 0 | 1 | 5 | 2 | 11 | 3 | 6 | 9 | 10 | 10 | 13 | 4 | ||||
% | 20.0 | 2.2 | 2.2 | 2.2 | 13.3 | 8.9 | 17.8 | 40.0 | 4.4 | 0.0 | 8.9 | 17.8 | 62.2 | 0.0 | 0.0 | 13.3 | 26.7 | 0.0 | 13.3 | 6.7 | 0.0 | 4.4 | 0.0 | 2.2 | 11.1 | 4.4 | 24.4 | 6.7 | 13.3 | 20.0 | 22.2 | 22.2 | 28.9 | 8.9 |
First, some Mφ transcription factors (TFs) were upregulated in more than 30% of the 34 diseases, including M1 TF STAT1 and three other Mφ TFs, namely HMGA1, E2F3, and NME1. Second, the diseases having Mφ TFs upregulated in more than 30% among the 34 diseases were of six types, namely #6 coronary artery disease, #12 Crohn's colitis, #28 hepatocellular cancer, #29 esophageal cancer, #32 ovarian carcinoma, and #33 lung cancer (For detailed expression data, see the Figures S13–S16). 1, Rheumatoid arthritis; 2, Systemic lupus erythematosus; 3, Psoriasis; 4, Asthma; 5, Myocardial infarction; 6, Coronary artery disease; 7, Abdominal aortic aneurysm; 8, Aortic occlusive disease; 9, Ulcerative colitis; 10, Gastritis; 11, Crohn's ileitis; 12, Crohn's colitis; 13, Tuberculous Meningitis coinfected with HIV; 14, Sepsis; 15, Chronic Hepatitis C virus; 16, Tuberculosis; 17, Type 2 diabetes; 18, Type 1 diabetes; 19, Metabolic syndrome; 20, Familial Hypercholesterolemia; 21, Chronic obstructive pulmonary disease; 22, Pulmonary arterial hypertension; 23, Asthma; 24, Pneumonia; 25, Gastric adenocarcinoma; 26, Hepatocellular cancer; 27, Colorectal adenocarcinoma; 28, Pancreatic cancer; 29, Esophageal cancer; 30, Breast Adenocarcinoma; 31, Prostate cancer; 32, Ovarian carcinoma; 33, Lung cancer; 34, Renal carcinoma.